$GYRE
Gyre Therapeutics, Inc. Common Stock
XNAS
Why is GYRE down today? It is at $6.55 (-0.61%), and our scanner flagged it 1 time on unusual volume this month. See the catalyst behind the move, real-time alerts the moment GYRE spikes, and full due diligence on GYRE — key stats, earnings, dilution and insider activity. Free.
Get free $GYRE alerts the moment volume spikes
Our scanner flagged $GYRE 1 time in the last 30 days. Create a free account to track $GYRE, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $6.55
- Change today
- -0.61%
- Previous close
- $6.59
- 52-week range
- $5.44 – $9.42
- Market cap
- $735M
- Institutional own.
- 9.31%
- Total held
- 18.1%
- Tradeable float
- 91.3M 82% of shares · after 9% insiders + 9% institutions
- Short interest
- 1.7M ▼ -4% vs prior · as of 2026-08-14
- Short % of float
- 1.9%
- Days to cover
- 31.1d
- Avg daily volume
- 86K
- Exchange
- XNAS
- 5mthin
- 1.4x
- 15mthin
- 1.4x
- 1hthin
- 1.1x
- 1D
- 0.1x
Get free GYRE + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $GYRE down today?
GYRE is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 1 unusual-volume and momentum alert on GYRE today, peaking at 2.5x its normal volume.
Likely catalyst1 August 2026 Building A New Protein Degrader Company For Unmet Medical NeedsReported development ETUARYTM has been the market-leading pirfenidone brand in China for treatment of idiopathic pulmonary fibrosis (IPF); FY26 ETUARYTM Total Revenue Guidance of $100.5-$111MM F351 adds a near-term revenue growth catalyst for theReported amplification Rb loss PTEN loss PI3K upregulation MYC overexpression Erα alterations ET Resistance CDK2/ cyclin E CDK4/6i Resistance [1, 4, 5] [6] [2,4] [2,5] [3] [2] [7] [4] [8] CCNE1 Amplification Prevalence (%) [1] MarketReported Opportunity & Unmet Medical Need Verzenio, Kisqali, and Ibrance ~$14.6B Total Global Revenues in 2025 Projected total global revenues between $25.8B - $35.7B by early 2030s ~50% of patients develop resistance to CDK4/6 inhibitors, from an SEC filing. Read it →Latest filingS-8Employee share plan registration (S-8)Aug 28, 2026 · 2 days agoAnalyst data via Nasdaq. Not investment advice.
Insiders
Insiders selling0 buys, 8 sells last 3 months (0/18 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Ye Weiguo Officer | Sold (automatic/other) | -3K | sold 0.4% | 700K | $19K at $6.35 | Jun 18, 26 |
Ye Weiguo Officer | Other | 3K | added 0.4% | 703K | $2K at $0.750 | Jun 18, 26 |
Ye Weiguo Officer | Sold (automatic/other) | -3K | sold 0.4% | 700K | $17K at $6.17 | Jun 11, 26 |
Ye Weiguo Officer | Other | 3K | added 0.4% | 703K | $2K at $0.750 | Jun 11, 26 |
Ye Weiguo Officer | Sold (automatic/other) | -6K | sold 0.9% | 700K | $40K at $6.21 | Jun 10, 26 |
Ye Weiguo Officer | Other | 6K | added 0.9% | 706K | $5K at $0.750 | Jun 10, 26 |
Ye Weiguo Officer | Sold (automatic/other) | -5K | sold 0.7% | 700K | $31K at $6.24 | Jun 10, 26 |
Ye Weiguo Officer | Other | 5K | added 0.7% | 705K | $4K at $0.750 | Jun 10, 26 |
Ye Weiguo Officer | Sold (automatic/other) | -15K 0.01% of company | sold 2.0% | 700K | $89K at $6.14 | Jun 9, 26 |
Ye Weiguo Officer | Sold (automatic/other) | -3K | sold 0.4% | 700K | $18K at $6.15 | Jun 9, 26 |
Ye Weiguo Officer | Other | 15K 0.01% of company | added 2.1% | 715K | $11K at $0.750 | Jun 9, 26 |
Ye Weiguo Officer | Other | 3K | added 0.4% | 703K | $2K at $0.750 | Jun 9, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Active shelfActive shelf on file — the company can issue new shares on demand (valid ~3 years). If $GYRE runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$GYRE Sentiment
BullishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$GYRE Activity
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
GYRE stock FAQ
Why is $GYRE down today?
GYRE is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 1 unusual-volume and momentum alert on GYRE today, peaking at 2.5x its normal volume.
What is the GYRE stock price today?
GYRE last traded at $6.55, down 0.61% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live GYRE alerts?
The GYRE Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged GYRE 1 time in the last 30 days.
What exchange is GYRE on?
GYRE (Gyre Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $735M.
Is GYRE good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge GYRE for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.